Regarding combination of manifestations, almost all CoEs would advise periodic screening similar to mutation‐positive patients in GN‐MEN1 patients with duodenopancreatic NETs, while a minority would advise so in patients with pHPT and pituitary adenomas. This evidence concerns the gene MEN1 and pituitary gland adenoma.